283 related articles for article (PubMed ID: 17319449)
1. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain.
Rauck RL; Bookbinder SA; Bunker TR; Alftine CD; Ghalie R; Negro-Vilar A; de Jong E; Gershon S
J Opioid Manag; 2006; 2(3):155-66. PubMed ID: 17319449
[TBL] [Abstract][Full Text] [Related]
2. A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial.
Rauck RL; Bookbinder SA; Bunker TR; Alftine CD; Ghalie R; Negro-Vilar A; de Jong E; Gershon S
J Opioid Manag; 2006; 2(6):325-8, 331-3. PubMed ID: 17326594
[TBL] [Abstract][Full Text] [Related]
3. A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial.
Rauck RL; Bookbinder SA; Bunker TR; Alftine CD; Gershon S; de Jong E; Negro-Vilar A; Ghalie R
J Opioid Manag; 2007; 3(1):35-43. PubMed ID: 17367093
[TBL] [Abstract][Full Text] [Related]
4. Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA): findings from a pilot study.
Rosenthal M; Moore P; Groves E; Iwan T; Schlosser LG; Dziewanowska Z; Negro-Vilar A
J Opioid Manag; 2007; 3(3):145-54. PubMed ID: 18027540
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
Hale ME; Dvergsten C; Gimbel J
J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
[TBL] [Abstract][Full Text] [Related]
7. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
Kopecky EA; Vaughn B; Lagasse S; O'Connor M
Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
Nicholson B; Ross E; Sasaki J; Weil A
Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
10. A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions--the ACCPT Study.
Adams EH; Chwiecko P; Ace-Wagoner Y; Mangefrida B; Duerden ME; Perdikis GC; Kunkel FA; Ghalie R
Pain Pract; 2006 Dec; 6(4):254-64. PubMed ID: 17129306
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
Peniston JH; Xiang Q; Gould EM
Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
[TBL] [Abstract][Full Text] [Related]
13. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
Gabrail NY; Dvergsten C; Ahdieh H
Curr Med Res Opin; 2004 Jun; 20(6):911-8. PubMed ID: 15200750
[TBL] [Abstract][Full Text] [Related]
14. Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: a pilot assessment of the CoDem protocol.
Samolsky Dekel BG; Tomasi M; Vasarri A; Gori A; Adversi M; Castagnoli A; Di Nino G; Melotti RM
J Opioid Manag; 2014; 10(1):29-38. PubMed ID: 24604567
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
Ueberall MA; Mueller-Schwefe GH
Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial.
Zecca E; Brunelli C; Bracchi P; Biancofiore G; De Sangro C; Bortolussi R; Montanari L; Maltoni M; Moro C; Colonna U; Finco G; Roy MT; Ferrari V; Alabiso O; Rosti G; Kaasa S; Caraceni A
J Pain Symptom Manage; 2016 Dec; 52(6):783-794.e6. PubMed ID: 27742577
[TBL] [Abstract][Full Text] [Related]
17. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.
Webster LR; Brewer R; Morris D; Cleveland JM; Setnik B
Postgrad Med; 2011 Sep; 123(5):155-64. PubMed ID: 21904098
[TBL] [Abstract][Full Text] [Related]
18. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation.
Roth SH; Fleischmann RM; Burch FX; Dietz F; Bockow B; Rapoport RJ; Rutstein J; Lacouture PG
Arch Intern Med; 2000 Mar; 160(6):853-60. PubMed ID: 10737286
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.
Hale ME; Fleischmann R; Salzman R; Wild J; Iwan T; Swanton RE; Kaiko RF; Lacouture PG
Clin J Pain; 1999 Sep; 15(3):179-83. PubMed ID: 10524470
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
